New US venture aiming for novel oncology targets
This article was originally published in Scrip
A new drug discovery venture, FORMA Therapeutics, has been set up in the US, with a focus on the identification of novel oncology targets. Most of the co-founders come from the Broad Institute, a medical research initiative set up by Harvard University and the Massachusetts Institute of Technology with philanthropic funding.
You may also be interested in...
The firm reorganized to focus on hemoglobinopathies and cancers after Celgene ended a multi-drug partnership. Also, Flagship funds a gene therapy start-up and brings in a business development veteran, Ultragenyx raises $320m in a royalty deal and Paratek secures up to $285m from BARDA.
This time we touch on Pfizer’s R&D plans, real-world evidence for coronavirus vaccines, a new approval in lung cancer, challenges for Galapagos, and Takeda's pipeline story.
Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.